Johnson & Johnson and Merck are laying off workers in China, according to a story from Bloomberg which cites reports from ...

Merck MRK stock closed at $97.44 on Wednesday, which is close to its 52-week low of $94.48. The company is facing several ...

Merck reported good news Tuesday on a more convenient version of its cancer drug Keytruda, a reassuring sign following ...

Worldwide, the company’s Gardasil franchise saw sales (PDF) slide 11% compared with last year to $2.3 billion. Merck attributed the decline to lower demand in China, which offset double-digit ...

But Merck's vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., posted another quarter of lighter-than-expected sales. But Merck's vaccine that ...

Merck reported a decline of 11% in sales of Gardasil to $2.31 billion, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., due to lower demand in ...

Oct 31 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's distributor there reduces inventories ...

Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Keytruda sales surged 17% YoY to $7.43B, while Gardasil sales dropped 11% to $2.31B due to reduced demand in China. Merck's Q3 sales reached $16.7 billion, a 4% YoY increase, beating the $16.5 ...